BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 11466344)

  • 1. Multiple paths for activation of naive CD8+ T cells: CD4-independent help.
    Wang B; Norbury CC; Greenwood R; Bennink JR; Yewdell JW; Frelinger JA
    J Immunol; 2001 Aug; 167(3):1283-9. PubMed ID: 11466344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
    Stober D; Jomantaite I; Schirmbeck R; Reimann J
    J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective immunity from naive CD8+ T cells activated in vitro with MHC class I binding immunogenic peptides and IL-2 in the absence of specialized APCs.
    Hauser C; Zipprich F; Leblond I; Wirth S; Hügin AW
    J Immunol; 1999 Jul; 163(1):330-6. PubMed ID: 10384132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naive CD8+ T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells.
    Wang B; Maile R; Greenwood R; Collins EJ; Frelinger JA
    J Immunol; 2000 Feb; 164(3):1216-22. PubMed ID: 10640733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison.
    Storni T; Bachmann MF
    J Immunol; 2004 May; 172(10):6129-35. PubMed ID: 15128799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial activation of neonatal CD11c+ dendritic cells and induction of adult-like CD8+ cytotoxic T cell responses by synthetic microspheres.
    Regner M; Martinez X; Belnoue E; Sun CM; Boisgerault F; Lambert PH; Leclerc C; Siegrist CA
    J Immunol; 2004 Aug; 173(4):2669-74. PubMed ID: 15294984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes.
    Blohm U; Roth E; Brommer K; Dumrese T; Rosenthal FM; Pircher H
    J Immunol; 2002 Nov; 169(10):5522-30. PubMed ID: 12421928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.
    Schnell S; Young JW; Houghton AN; Sadelain M
    J Immunol; 2000 Feb; 164(3):1243-50. PubMed ID: 10640737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutting edge: CCR7+ and CCR7- memory T cells do not differ in immediate effector cell function.
    Unsoeld H; Krautwald S; Voehringer D; Kunzendorf U; Pircher H
    J Immunol; 2002 Jul; 169(2):638-41. PubMed ID: 12097363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective delivery of augmented IL-2 receptor signals to responding CD8+ T cells increases the size of the acute antiviral response and of the resulting memory T cell pool.
    Cheng LE; Greenberg PD
    J Immunol; 2002 Nov; 169(9):4990-7. PubMed ID: 12391213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo.
    Norbury CC; Princiotta MF; Bacik I; Brutkiewicz RR; Wood P; Elliott T; Bennink JR; Yewdell JW
    J Immunol; 2001 Apr; 166(7):4355-62. PubMed ID: 11254689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting the efficiency of CD8+ T cell cross-priming with exogenous antigens.
    Maecker HT; Ghanekar SA; Suni MA; He XS; Picker LJ; Maino VC
    J Immunol; 2001 Jun; 166(12):7268-75. PubMed ID: 11390476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
    Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
    Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells.
    Bonini C; Lee SP; Riddell SR; Greenberg PD
    J Immunol; 2001 Apr; 166(8):5250-7. PubMed ID: 11290810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
    J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.
    Hermans IF; Ritchie DS; Yang J; Roberts JM; Ronchese F
    J Immunol; 2000 Mar; 164(6):3095-101. PubMed ID: 10706699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
    Storni T; Lechner F; Erdmann I; Bächi T; Jegerlehner A; Dumrese T; Kündig TM; Ruedl C; Bachmann MF
    J Immunol; 2002 Mar; 168(6):2880-6. PubMed ID: 11884458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
    Kelleher M; Beverley PC
    J Immunol; 2001 Dec; 167(11):6247-55. PubMed ID: 11714787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.